Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Mittmann

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Current Oncology (Toronto, Ont.)|May 3, 2019
Why are we organizing another costing supplement in <i>Current Oncology</i>?N Mittmann
Journal of Clinical Psychopharmacology|February 1, 1996
Repetitive publication, meta-analysis, and adverse eventsN Mittmann, S R Knowles
Current Oncology (Toronto, Ont.)|March 18, 2016
Importance of cost estimates and cost studiesN Mittmann, C de Oliveira
Current Oncology (Toronto, Ont.)|April 21, 2011
Rash rates with egfr inhibitors: meta-analysisN Mittmann, S J Seung
Spinal Cord|August 3, 2013
The value of health economics research in spinal cord injuryD G T Whitehurst, N Mittmann
Skin Therapy Letter|May 18, 2004
Intravenous immunoglobulin: use in dermatologyP R Mydlarski, N Mittmann, N H Shear
Pharmacoeconomics|October 28, 1999
Utility scores for chronic conditions in a community-dwelling populationN Mittmann, K Trakas, N Risebrough, et al.
Drugs & Aging|September 1, 1995
Recent advances in geriatric psychopharmacologyC A Naranjo, N Herrmann, N Mittmann, et al.
Current Oncology (Toronto, Ont.)|February 25, 2010
Cost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancerN Mittmann, S Verma, M Koo, et al.
Skin Therapy Letter|March 16, 2007
IVIG for the treatment of toxic epidermal necrolysisN Mittmann, B C Chan, S Knowles, et al.
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Current Oncology (Toronto, Ont.)|May 3, 2019
Why are we organizing another costing supplement in <i>Current Oncology</i>?N Mittmann
Journal of Clinical Psychopharmacology|February 1, 1996
Repetitive publication, meta-analysis, and adverse eventsN Mittmann, S R Knowles
Current Oncology (Toronto, Ont.)|March 18, 2016
Importance of cost estimates and cost studiesN Mittmann, C de Oliveira
Current Oncology (Toronto, Ont.)|April 21, 2011
Rash rates with egfr inhibitors: meta-analysisN Mittmann, S J Seung
Spinal Cord|August 3, 2013
The value of health economics research in spinal cord injuryD G T Whitehurst, N Mittmann
Skin Therapy Letter|May 18, 2004
Intravenous immunoglobulin: use in dermatologyP R Mydlarski, N Mittmann, N H Shear
Pharmacoeconomics|October 28, 1999
Utility scores for chronic conditions in a community-dwelling populationN Mittmann, K Trakas, N Risebrough, et al.
Drugs & Aging|September 1, 1995
Recent advances in geriatric psychopharmacologyC A Naranjo, N Herrmann, N Mittmann, et al.
Current Oncology (Toronto, Ont.)|February 25, 2010
Cost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancerN Mittmann, S Verma, M Koo, et al.
Skin Therapy Letter|March 16, 2007
IVIG for the treatment of toxic epidermal necrolysisN Mittmann, B C Chan, S Knowles, et al.
Pageof 6